Procalcitonin Levels in the Management of COPD Exacerbations

Procalcitonin Levels in the Management of COPD Exacerbations Posted By:
...

The use of procalcitonin-based protocols to guide the decision to administer antibiotics has been evaluated in infections of different origins and settings. A well-conducted systematic review supported the effectiveness of procalcitonin-guided protocols in lower respiratory tract infections, based on evidence of moderate quality from GRADE (Grading of Recommendations, Assessment, Development and Evaluation). However, these results do not necessary imply that such protocols would be effective in patients presenting with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), since the chronically elevated baseline inflammatory status and the chronic bacterial colonization of the airways of patients with COPD could affect the serum procalcitonin levels—and its utilization to help guide antibiotic therapy in a patient with AECOPD is controversial. However, a substantial fraction of acute COPD exacerbations are caused by viruses, and some experts use procalcitonin to help guide antibiotic discontinuation in patients with non-severe AECOPD.

Procalcitonin synthesis pathways vary in different inflammatory states. In the absence of systemic inflammation, procalcitonin synthesis is restricted to thyroid neuroendocrine cells, and the protein is not released into the blood until it is split into its mature form, calcitonin. Thus, serum procalcitonin is typically undetectable in healthy persons when standard assays are used. Not all bacterial infections cause procalcitonin to rise, or rise to the same degree. Typical bacteria, such as Streptococcus pneumoniae or Hemophilus influenzae, tend to cause greater rises in procalcitonin than atypical bacteria.

The reference value of procalcitonin in adults and children older than 72 hours is 0.15 ng/mL or less (reference values have not been established in infants younger than 72 hours). In healthy adults, the reference range of procalcitonin is below the level of detection. The half-life of procalcitonin is 25 to 30 hours.

While procalcitonin use in patients hospitalized with AECOPD has been shown to reduce antibiotic exposure without increasing adverse events in several trials, this benefit has not been consistently demonstrated in all trials and treatment settings. Additional data in varying clinical settings are needed before broad use can be recommended.

References
  • De Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819-827.
  • Christ-Crain M, Müller B. Procalcitonin in bacterial infections--hype, hope, more or less? Swiss Med Wkly. 2005;135:451.
  • Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol. 2010;48:2325.
  • Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(Suppl 1):S57.
  • Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health. 2013;8:1297-1371.
  • Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9:CD007498.
  • Van der Does Y, Rood PP, Haagsma JA, et al. Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review. Am J Emerg Med. 2016;34:1286-1293.
  • Verduri A, Luppi F, D'Amico R, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PloS One. 2015;10:e0118241.

Share

Filed under: Infectious Diseases , Pulmonary Medicine

Related
HIV Prevention and Testing Is Not Bound By Age

HIV Prevention and Testing Is Not Bound By Age

In 2006, the CDC updated the HIV testing guidelines to recommend routine opt-out testing for people ...

Filed under: Infectious Diseases, Preventive Medicine, Public Health, NPs & PAs


Continue Reading
Addressing ASCVD Risk in HIV: An Update to the DHHS HIV Guidelines

Addressing ASCVD Risk in HIV: An Update to the DHH ...

The incidence of atherosclerotic cardiovascular disease (ASCVD) is estimated to be twice as high in ...

Filed under: Infectious Diseases, Preventive Medicine, Public Health, Cardiometabolic, NPs & PAs


Continue Reading
Doxy-PEP: A New Opportunity to Reduce STIs

Doxy-PEP: A New Opportunity to Reduce STIs

According to CDC data from 2022, more than 2.5 million cases of chlamydia, gonorrhea, and syphilis w ...

Filed under: Nurses Week, Infectious Diseases, Urology, Preventive Medicine, Public Health, Substance Abuse, NPs & PAs


Continue Reading
Treatment of COVID-19: Practical Questions and Insights for NPs and PAs

Treatment of COVID-19: Practical Questions and Ins ...

Is it reasonable to prescribe a 5-day supply of an oral antiviral to people traveling abroad with ri ...

Filed under: Infectious Diseases, Public Health, NPs & PAs


Continue Reading
Assessment of COVID-19: Practical Questions and Insights for NPs and PAs

Assessment of COVID-19: Practical Questions and In ...

How long should people isolate when they test positive for COVID-19?The CDC recommends that one shou ...

Filed under: Infectious Diseases, Public Health, NPs & PAs


Continue Reading
Tackling Disparities in HIV Prevention

Tackling Disparities in HIV Prevention

Racial and ethnic disparities have been a problem in the HIV epidemic since the very beginning. Rece ...

Filed under: Infectious Diseases, Women's Health, Preventive Medicine, Public Health, NPs & PAs


Continue Reading